Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Infections, Cytomegalovirus
Interventions
DRUG

Letermovir 240 mg Oral Tablet

Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.

Trial Locations (1)

14004

Hospital Universitario Reina Sofia, Córdoba

All Listed Sponsors
collaborator

MERCK SHARP & DOHME DE ESPAÑA S.A.

UNKNOWN

lead

Maimónides Biomedical Research Institute of Córdoba

OTHER